ARPA-H Insider Joins EverGlade, Highlighting New R&D Gatekeepers

HOUSTON, TX – August 20, 2026 – In a move that underscores the intensifying competition for federal health innovation funding, advisory firm EverGlade announced today it has hired Dr. Kate Teffer, a former scientific advisor from the nascent but powerful Advanced Research Projects Agency for Health (ARPA-H). The hire is more than just a personnel update; it's a telling indicator of the evolving landscape where deep, insider knowledge of byzantine federal processes is becoming the most valuable commodity for life sciences innovators.

Dr. Teffer joins EverGlade as a Senior Technical Strategist, bringing with her an intimate understanding of the agency tasked with funding America's most ambitious biomedical moonshots. This isn't just another consultant hire; it's the strategic acquisition of institutional knowledge at a critical juncture for both the agency and the companies seeking its support.

A Strategic Coup in the High-Stakes Funding Game

For EverGlade, a firm that has already carved out a significant niche by securing over $3 billion in federal awards for its clients, bringing Dr. Teffer onboard is a decisive strategic maneuver. The firm specializes in navigating the entire federal funding lifecycle, from proposal to post-award execution, and Teffer's experience is a near-perfect schematic of that process from the government's side.

"Kate brings firsthand insight into how federal health agencies evaluate scientific concepts and define program success," said Giacomo Apadula, CEO of EverGlade, in the official announcement. Her ability to "translate complex science into high impact, fundable programs," he noted, would offer clients an "unparalleled perspective."

This perspective is already proving lucrative. EverGlade has recently guided clients to significant ARPA-H awards, including helping SonALAsense secure up to $46 million for an ultrasound-based cancer therapy and Landmark Bio obtain up to $18.3 million. These successes demonstrate a proficiency in aligning novel science with ARPA-H's high-risk, high-reward mandate. Adding the very individual who helped write the agency's funding announcements and led scientific reviews for its earliest projects is a clear signal that EverGlade intends to cement its position as the premier guide to the ARPA-H ecosystem.

Dr. Teffer's role within ARPA-H's Health Science Futures (HSF) Mission Office was foundational. She co-authored the original Broad Agency Announcement and Innovation Solutions Opening—the very documents that define the rules of engagement for applicants. Her move to the private sector effectively transfers that architectural knowledge to the other side of the table, offering clients a masterclass in how to build a proposal that doesn't just meet the criteria, but anticipates the agency's strategic thinking.

The Architect Moves Outside the Agency

Dr. Teffer's career trajectory provides a compelling narrative on the flow of talent between public service and private enterprise. With over a decade of experience advising federal bodies like the NIH, DoD, and VA even before her ARPA-H tenure, she represents a class of professional who has made a career of translating between scientific possibility and bureaucratic reality.

"ARPA-H was built on a simple premise: the most challenging health problems facing Americans deserve the same urgency and ambition we bring to national security," Dr. Teffer stated. "I spent over two years inside the agency seeing what it takes for a bold scientific idea to become a funded research effort."

Her decision to join EverGlade, she explained, was driven by a desire to help more innovators successfully make that leap. The move highlights a critical bottleneck in the innovation pipeline: brilliant science often fails not in the lab, but in the grant application. The complexity of federal funding mechanisms, particularly the unique structures employed by ARPA-H, creates a formidable barrier to entry for the very startups and research groups the agency hopes to attract.

ARPA-H, modeled on the legendary Defense Advanced Research Projects Agency (DARPA), operates differently than traditional funding bodies like the NIH. It utilizes flexible vehicles like "Other Transactions" (OTs) and "Innovative Solution Openings" (ISOs) that allow for more collaborative and milestone-driven project management. While this flexibility is a strength, it also creates a steep learning curve for applicants accustomed to standard grant formats. Someone like Dr. Teffer, who was instrumental in crafting and reviewing these novel solicitations, is uniquely positioned to demystify the process.

Navigating the Labyrinth: The Rise of the Specialist Advisor

The need for specialist advisors like Dr. Teffer is a direct consequence of the broader federal funding environment. While Congress has largely protected research budgets from proposed cuts—sustaining the NIH budget at $47.2 billion for FY2026—the competition for those dollars has never been fiercer. Success rates for some programs, like the NIH's Small Business Innovation Research (SBIR) Phase I awards, have recently fallen to a record low of 9.9%.

In this hyper-competitive climate, simply having good science is no longer enough. Innovators must present their work within a strategic narrative that aligns perfectly with an agency's mission, priorities, and procedural quirks. This has fueled the growth of a sophisticated advisory industry, with firms like EverGlade acting as a combination of Sherpa, translator, and strategist for companies navigating the federal landscape.

While EverGlade has demonstrated its value in the ARPA-H space, its portfolio extends to securing DoD awards for domestic manufacturing and supporting applicants for Department of Energy and CHIPS Act funding. This diversification highlights a broader trend: as the government increasingly uses complex, multi-agency initiatives to tackle national priorities from pandemic preparedness to semiconductor manufacturing, the value of cross-cutting expertise only grows.

The Revolving Door and the New R&D Gatekeepers

The hiring of former government officials into the consulting firms that service their old agencies is a long-standing practice, often referred to as the "revolving door." This trend is particularly pronounced in sectors with high-value, complex government contracting, and biomedical research is now firmly in that category.

While the term can carry negative connotations, the practice is governed by a strict set of ethical and legal guardrails. Federal laws, including 18 U.S.C. § 207 and the Procurement Integrity Act, impose post-government employment restrictions, including lifetime bans on a former employee switching sides on specific matters they were personally involved in. These rules are designed to prevent conflicts of interest and the improper use of inside information.

Firms like EverGlade must navigate these regulations carefully, ensuring that new hires like Dr. Teffer provide strategic, high-level guidance rather than leveraging privileged information on active procurements. The value she brings is not in knowing who will win a contract, but in understanding the deep structure of how winning proposals are constructed and evaluated. She is less an informant and more an architect, capable of designing a project that speaks the agency's native language.

Dr. Teffer's transition from public servant to private strategist is a powerful illustration of the new realities of public-private partnership in health innovation. As the government builds more ambitious and complex vehicles to drive scientific progress, it simultaneously creates a market for the specialized knowledge required to operate them, turning former insiders into the new gatekeepers of American innovation.